Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to be releasing its earnings data before the market opens on Tuesday, April 30th. Analysts expect Nautilus Biotechnology to post earnings of ($0.16) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter in the previous year, the business earned ($0.11) EPS. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Stock Performance

NAUT stock opened at $2.49 on Friday. The firm has a fifty day moving average price of $2.66 and a 200 day moving average price of $2.81. Nautilus Biotechnology has a fifty-two week low of $2.16 and a fifty-two week high of $4.65. The firm has a market cap of $311.49 million, a PE ratio of -4.79 and a beta of 1.20.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 18,854 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was purchased at an average cost of $2.89 per share, with a total value of $54,488.06. Following the completion of the acquisition, the chief executive officer now owns 10,050,014 shares in the company, valued at approximately $29,044,540.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Sujal M. Patel purchased 18,854 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $2.89 per share, for a total transaction of $54,488.06. Following the completion of the transaction, the chief executive officer now directly owns 10,050,014 shares in the company, valued at $29,044,540.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sujal M. Patel purchased 12,044 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was bought at an average price of $2.84 per share, with a total value of $34,204.96. Following the completion of the transaction, the chief executive officer now owns 10,064,488 shares of the company’s stock, valued at $28,583,145.92. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 38,303 shares of company stock valued at $108,316. 42.50% of the stock is owned by corporate insiders.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.